• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medication are ineffective. The individual approach to treatment could be the solution.

Cue is an intervention platform that transforms sensor data collected from smartphones into personalized micro-interventions for improving mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and reveal distinct features that deterministically change mood with time.

Predictors of Mood

Depression is a major cause of mental illness across the world.1 Yet, only half of those affected receive treatment. In order to improve outcomes, healthcare professionals must be able to recognize and treat patients with the highest chance of responding to certain treatments.

The ability to tailor depression treatments is one method to achieve this. Utilizing mobile phone sensors as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new holistic ways to treat depression to predict which patients will benefit from the treatments they receive. Two grants were awarded that total over $10 million, they will use these techniques to determine the biological and behavioral factors that determine the response to antidepressant medication and psychotherapy.

So far, the majority of research on predictors for perimenopause depression treatment treatment effectiveness has been focused on sociodemographic and clinical characteristics. These include factors that affect the demographics such as age, gender and education, clinical characteristics including the severity of symptoms and comorbidities and biological markers such as neuroimaging and genetic variation.

A few studies have utilized longitudinal data to predict mood in individuals. Many studies do not take into consideration the fact that moods vary significantly between individuals. Therefore, it is essential to create methods that allow the identification of individual differences in mood predictors and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to identify patterns of behaviour and emotions that are unique to each individual.

In addition to these modalities, the team also developed a machine-learning algorithm to model the changing variables that influence each person's mood. The algorithm combines these personal variations into a distinct "digital phenotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, a psychometrically validated scale for assessing severity of symptom. The correlation was not strong, however (Pearson r = 0,08; BH adjusted P-value 3.55 x 10 03) and varied widely between individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1, but it is often underdiagnosed and undertreated2. Depression disorders are rarely treated because of the stigma associated with them and the lack of effective treatments.

To aid in the development of a personalized treatment, it is crucial to determine the predictors of symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which are unreliable and only detect a few symptoms associated with depression.

Using machine learning to integrate continuous digital behavioral phenotypes of a person captured by smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, the CAT-DI) together with other predictors of severity of symptoms could improve diagnostic accuracy and increase the effectiveness of treatment for depression. These digital phenotypes allow continuous, high-resolution measurements as well as capture a wide variety of unique behaviors and activity patterns that are difficult to document with interviews.

The study included University of California Los Angeles students who had mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or to clinical treatment based on the severity of their depression. Patients who scored high on the CAT-DI scale of 35 65 were assigned online support via the help of a coach. Those with scores of 75 patients were referred for in-person psychotherapy.

At the beginning of the interview, participants were asked an array of questions regarding their personal demographics and psychosocial characteristics. These included age, sex education, work, and financial situation; whether they were divorced, partnered or single; the frequency of suicidal thoughts, intentions or attempts; as well as the frequency with that they consumed alcohol. Participants also rated their level of depression symptom severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted every other week for the participants who received online support and every week for those who received in-person support.

Predictors of the Reaction to Treatment

Personalized depression treatment is currently a major research area and a lot of studies are aimed at identifying predictors that will help clinicians determine the most effective drugs for each person. Particularly, pharmacogenetics is able to identify genetic variations that affect how the body metabolizes antidepressants. This lets doctors select the medication that will likely work best for every patient, minimizing time and effort spent on trials and errors, while avoid any negative side negative effects.

Another promising approach is to develop prediction models combining information from clinical studies and neural imaging data. These models can be used to determine the best drug to treat anxiety and depression combination of variables that is predictive of a particular outcome, such as whether or not a medication will improve the mood and symptoms. These models can be used to predict the response of a patient to a treatment, which will help doctors to maximize the effectiveness.

A new generation of machines employs machine learning methods such as the supervised and classification algorithms, regularized logistic regression and tree-based techniques to combine the effects of multiple variables and increase the accuracy of predictions. These models have shown to be useful in forecasting treatment outcomes, such as the response to antidepressants. These approaches are becoming more popular in psychiatry, and are likely to become the standard of future clinical practice.

In addition to ML-based prediction models, research into the underlying mechanisms of depression continues. Recent findings suggest that depression is connected to the malfunctions of certain neural networks. This suggests that an the treatment for depression Treatment Free will be individualized based on targeted treatments that target these circuits in order to restore normal functioning.

Internet-delivered interventions can be an option to achieve this. They can offer a more tailored and individualized experience for patients. One study found that an internet-based program helped improve symptoms and led to a better quality of life for MDD patients. A randomized controlled study of a customized treatment for depression showed that a substantial percentage of patients saw improvement over time as well as fewer side effects.

Predictors of adverse effects

A major challenge in personalized depression treatment involves identifying and predicting the antidepressant medications that will have the least amount of side effects or none at all. Many patients take a trial-and-error approach, with a variety of medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics offers a new and exciting method of selecting antidepressant medications that is more effective and precise.

Several predictors may be used to determine which antidepressant is best to prescribe, including genetic variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and comorbidities. However, identifying the most reliable and accurate factors that can predict the effectiveness of a particular treatment will probably require randomized controlled trials of considerably larger samples than those that are typically part of clinical trials. This is because the detection of interaction effects or moderators can be a lot more difficult in trials that focus on a single instance of treatment per person instead of multiple sessions of treatment over time.

Furthermore the prediction of a patient's response to a particular medication is likely to need to incorporate information regarding symptoms and comorbidities as well as the patient's prior subjective experience of its tolerability and effectiveness. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables appear to be reliably related to response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics in treatment for depression is in its infancy and there are many obstacles to overcome. First is a thorough understanding of the genetic mechanisms is essential, as is an understanding of what constitutes a reliable predictor for treatment response. In addition, ethical issues, such as privacy and the appropriate use of personal genetic information must be considered carefully. In the long-term, pharmacogenetics may be a way to lessen the stigma associated with mental health treatment and to improve the outcomes of those suffering with depression. As with any psychiatric approach it is essential to give careful consideration and implement the plan. In the moment, it's best treatment for anxiety and depression to offer patients various depression medications that are effective and urge them to talk openly with their doctors.